CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $58.97B, higher than 95% of all stocks globally
- FinancialsAltman Z-Score 9.3: safe zone
- Interpretations6 currently firing — 6
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
395.09BCNY58.97B · vs all stocks (USD)
Trailing P/E
92.60xvs Biotechnology peers
Revenue (TTM)
41.04BCNY6.13B · vs all stocks (USD)
Profit Margin
10.70%vs Biotechnology peers
Beta
0.5160xvs all stocks
52-Week Change
-13.25%vs all stocks
Market Capitalization
395.09BCNY58.97B · vs all stocks (USD)
Enterprise Value
2.51TCNY375.18B · vs all stocks (USD)
Trailing P/E
92.60xvs Biotechnology peers
Forward P/E
49.00xvs Biotechnology peers
PEG Ratio
0.7202xvs Biotechnology peers
Price to Sales (TTM)
64.21xvs Biotechnology peers
Price to Book (MRQ)
11.32xvs Biotechnology peers
Enterprise to Revenue
61.24xvs Biotechnology peers
Gross Margin
89.76%vs Biotechnology peers
Profit Margin
10.70%vs Biotechnology peers
Operating Margin
19.06%vs Biotechnology peers
Return on Assets (TTM)
7.46%vs Biotechnology peers
Return on Equity (TTM)
14.66%vs Biotechnology peers
Revenue (TTM)
41.04BCNY6.13B · vs all stocks (USD)
Revenue per Share (TTM)
55.27CNYUpdated Sep 22, 2026Quarterly Revenue Growth
29.60%vs Biotechnology peers
Gross Profit (TTM)
36.48BCNY5.45B · vs all stocks (USD)
EBITDA (TTM)
1.18BCNY175.44M · vs all stocks (USD)
Net Income (TTM)
4.39BCNY655.41M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
151.30%vs Biotechnology peers
Operating Cash Flow (TTM)
9.94BCNY1.48B · vs all stocks (USD)
Levered Free Cash Flow (TTM)
5.89BCNY878.62M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
5.34BUSDFY2025 · Dec 31, 2025Cost of Goods Sold
668.54MUSDFY2025 · Dec 31, 2025Gross Profit
4.67BUSDFY2025 · Dec 31, 2025Operating Income
447.14MUSDvs all stocks (USD)
Pre-tax Income
416.85MUSDFY2025 · Dec 31, 2025Income Tax Expense
129.92MUSDFY2025 · Dec 31, 2025Net Income
286.93MUSDFY2025 · Dec 31, 2025EBIT
475.09MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
616.77MUSDFY2025 · Dec 31, 2025Research & Development
2.15BUSDFY2025 · Dec 31, 2025Selling, General & Administrative
2.08BUSDFY2025 · Dec 31, 2025Non-operating Interest Income
70.50MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
58.23MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
286.93MUSDFY2025 · Dec 31, 2025Operating Cash Flow
739.60MUSDFY2025 · Dec 31, 2025Free Cash Flow
553.76MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
4.61BUSDFY2025 · Dec 31, 2025Interest Paid
52.45MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
286.93MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
141.69MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
9.47MUSDFY2025 · Dec 31, 2025Stock-based Compensation
510.86MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-88.48MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-164.95MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
79.83MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-35.74MUSDFY2025 · Dec 31, 2025Capital Expenditures
-185.84MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-80.69MUSDFY2025 · Dec 31, 2025Purchase of Investments
-11.83MUSDFY2025 · Dec 31, 2025Sale of Investments
3.45MUSDFY2025 · Dec 31, 2025Other Investing Activity
-1.24MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-195.46MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
850.59MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-1.08BUSDFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-811.11MUSDFY2025 · Dec 31, 2025Other Financing Charges
859.37MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-181.61MUSDFY2025 · Dec 31, 2025Shares Outstanding
1.47BSharesUpdated Sep 22, 2026Float Shares
1.05BSharesUpdated Sep 22, 2026% Held by Insiders
2.58%vs all stocks
% Held by Institutions
31.23%vs all stocks
Total Cash (MRQ)
34.14BCNY5.10B · vs all stocks (USD)
Total Cash per Share (MRQ)
3.45CNYUpdated Sep 22, 2026Total Debt (MRQ)
13.72BCNY2.05B · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.3961xvs Biotechnology peers
Current Ratio (MRQ)
3.40xvs Biotechnology peers
Book Value per Share (MRQ)
23.63CNYUpdated Sep 22, 2026Total Assets
8.19BUSDvs all stocks (USD)
Total Current Assets
6.23BUSDFY2025 · Dec 31, 2025Total Liabilities
3.83BUSDFY2025 · Dec 31, 2025Total Non-current Assets
1.95BUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
2.00BUSDFY2025 · Dec 31, 2025Total Current Liabilities
1.83BUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
4.55BUSDFY2025 · Dec 31, 2025Accounts Receivable
865.08MUSDFY2025 · Dec 31, 2025Inventory
608.23MUSDFY2025 · Dec 31, 2025Accounts Payable
479.04MUSDFY2025 · Dec 31, 2025Short-term Debt
77.99MUSDFY2025 · Dec 31, 2025Other Current Liabilities
121.06MUSDFY2025 · Dec 31, 2025Long-term Debt
1.01BUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
879.77MUSDFY2025 · Dec 31, 2025Common Stock (Book)
144.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-8.32BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
4.36BUSDvs all stocks (USD)
52-Week Low
205.51CNYUpdated Sep 22, 202652-Week High
324.30CNYUpdated Sep 22, 202652-Week Change
-13.25%vs all stocks
Beta
0.5160xvs all stocks
50-Day MA
271.63CNYUpdated Sep 22, 2026200-Day MA
259.53CNYUpdated Sep 22, 2026Avg 10-Day Volume
2.74MSharesUpdated Sep 22, 2026Avg 30-Day Volume
4.25MSharesUpdated Sep 22, 2026Diluted EPS (TTM)
2.89CNYUpdated Sep 22, 2026Other Income / Expense
-42.55MUSDFY2025 · Dec 31, 20256 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Diagnostic
High OCF-to-NI With Multi-Year Gross-Profit Growth and Elevated-Margin-With-Deceleration
Cash covers reported profit and gross profit is up, with margins high and growth slowing.
Reads
Cash-Backed Growth Configuration
Revenue has grown steadily, and the cash arriving matches reported profit.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 9.3: safe zoneNotable
Altman Z-Score: 9.30
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $58.97B, higher than 95% of all stocks globallySignificant
Market cap (USD): 58,974,815,376.362Global P95: 25,554,966,472.502
Revenue is $6.13B, above the global median of $548.88MNotable
Revenue (USD): 6,126,172,919.026Global Median: 548,883,780.48
Levered free cash flow is $878.62M, above the global median of $18.73MNotable
Levered free cash flow (USD): 878,621,721.419Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
argenx SE
Tier 1ProductionApproval-Gated PipelineRule
Boston Scientific Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Bayer AG
Tier 1ProductionApproval-Gated PipelineRuleFlow
UCB SA
Tier 1ProductionApproval-Gated PipelineRuleRisk
Merck KGaA
Tier 1ProductionApproval-Gated PipelineRuleFlow
Edwards Lifesciences Corporation
Tier 1ProductionApproval-Gated PipelineRule
Siemens Healthineers AG
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sun Pharmaceutical Industries Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Samsung Biologics Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Teva Pharmaceutical Industries Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Maruchiyo Yamaokaya Corp.
6 interpretationsCash-Backed Growth ConfigurationRevenue Growing With Receivables GrowingOperating Income Growing With Multi-Year Revenue GrowthHigh OCF-to-NI With Multi-Year Gross-Profit Growth and Elevated-Margin-With-DecelerationIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin Elevated
Alnylam Pharmaceuticals Inc.
6 interpretationsCash-Backed Growth ConfigurationRevenue Growing With Receivables GrowingOperating Income Growing With Multi-Year Revenue GrowthHigh OCF-to-NI With Multi-Year Gross-Profit Growth and Elevated-Margin-With-DecelerationIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin Elevated
Keeper Technical Laboratory
5 interpretationsCash-Backed Growth ConfigurationRevenue Growing With Receivables GrowingOperating Income Growing With Multi-Year Revenue GrowthIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin Elevated